IPO后，Apnimed在华尔街上市后股价上涨

2026-08-25 23:31

Apinimed (APMD), which just had its IPO on July 31, is up ~11% in Tuesday morning trading after a pair of new positive Street initiations.
BofA Securities started the sleep drug developer off as a buy, citing the promise of its lead candidate, Oxnimbi (AD109), for obstructive sleep apnea.
Analyst Jason Gerberry said that AD109, a fixed-dose combination of atomoxetine and aroxybutynin, provides a differentiated approach, adding that "Oxnimbi was studied across mild-to-severe OSA and could address much of the population outside the current Zepbound label."
Cantor Fitzgerald's Josh Schimmer initiated Apnimed at buy, noting that its data makes it approvable. He is projecting an H1 2027 launch.
Schimmer, who himself has OSA, wrote, "While specialists we've spoken to anticipate many CPAP-tolerant patients asking for a prescription (like I will), they expect to be much more aggressive recommending it for patients who aren't compliant with their devices."
Gerberry has a $41 price target (~60% upside based on Aug. 24 close), while Schimmer's is $60 (~134% upside).

More on Apnimed, Inc.